{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:59:09Z","timestamp":1790657949316,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Orbital decompression is an effective surgery for reducing orbital congestion and proptosis for patients with thyroid eye disease (TED). However, it is commonly stated that elective orbital decompression, i.e., for reasons other than compressive optic neuropathy, should await the quiescent phase of the disease. The reason is to avoid inducing a flare-up of the orbitopathy secondary to surgical inflammation. Still, this means that patients with moderate to severe TED who are suffering from symptoms associated with TED must wait months to years before initiating surgical treatment. The purpose of this study is to evaluate the effectiveness of orbital apex decompression combined with intraorbital corticosteroid injection in patients with active TED, defined as Clinical Activity Score (CAS) \u22653.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center cohort study included patients with active TED (pre-operative CAS \u2265 3) who underwent single or staged orbital decompression between February 2023 and September 2025. All lateral wall decompressions included an intraorbital injection of a combination triamcinolone and dexamethasone as part of the operative technique. Primary outcomes included change in CAS, change in proptosis, and postoperative disease progression (\u2265 2-point increase in CAS at \u2265 8 weeks). Secondary analysis compared outcomes in patients with and without perioperative treatment using disease-modifying therapy (DMT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-six patients met inclusion criteria; 14 had preoperative dysthyroid optic neuropathy. Mean CAS decreased from 4.7 to 1.6 (\u0394 \u20133.1; 95% CI \u20133.92 to \u20132.36), and mean proptosis decreased from 22.7\u00a0mm to 19.7\u00a0mm (\u0394 \u20133.0 mm; 95% CI \u20133.28 to \u20132.23). One patient with severe TED met criteria for postoperative disease progression. Outcomes were consistent across subgroups regardless of perioperative DMT exposure. No patients developed new-onset diplopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Orbital decompression combined with intraorbital corticosteroid injection during active TED was associated with clinically meaningful reductions in CAS and proptosis, with infrequent postoperative deterioration and no major surgical complications. These findings provide real-world evidence supporting use of this combined approach during active disease, including in patients without dysthyroid optic neuropathy. These results are specific to a particular surgical technique and to the perioperative management of underlying thyroid status and risk factors associated with TED exacerbation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fopht.2026.1935053","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:42:42Z","timestamp":1790656962000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Orbital decompression with intraorbital corticosteroid injection during the active phase of thyroid eye disease: outcomes in a real-world cohort"],"prefix":"10.3389","volume":"6","author":[{"given":"Adam J.","family":"Neuhouser","sequence":"first","affiliation":[{"name":"Kahana Oculoplastic and Orbital Surgery","place":["Livonia, MI, United States"]},{"name":"Department of Ophthalmology, Corewell Health William Beaumont University Hospital Eye Institute","place":["Royal Oak, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Skender","sequence":"additional","affiliation":[{"name":"Kahana Oculoplastic and Orbital Surgery","place":["Livonia, MI, United States"]},{"name":"Department of Ophthalmology, Corewell Health William Beaumont University Hospital Eye Institute","place":["Royal Oak, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Z.","family":"Spadaro","sequence":"additional","affiliation":[{"name":"Kahana Oculoplastic and Orbital Surgery","place":["Livonia, MI, United States"]},{"name":"Department of Ophthalmology, Corewell Health William Beaumont University Hospital Eye Institute","place":["Royal Oak, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Kahana","sequence":"additional","affiliation":[{"name":"Kahana Oculoplastic and Orbital Surgery","place":["Livonia, MI, United States"]},{"name":"Department of Ophthalmology, Corewell Health William Beaumont University Hospital Eye Institute","place":["Royal Oak, MI, United States"]},{"name":"Department of Ophthalmology, Oakland University William Beaumont School of Medicine","place":["Rochester, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.380","article-title":"Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy","volume":"120","author":"Kazim","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/iio.0000000000000355","article-title":"Thyroid eye disease: pathogenic risk factors","volume":"61","author":"Do","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"249125","DOI":"10.1155\/2015\/249125","article-title":"Graves\u2019 ophthalmopathy","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/794984","article-title":"Reduction of orbital inflammation following decompression","volume":"2013","author":"Oh","year":"2013","journal-title":"BioMed Res Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.120","article-title":"TSH-receptor antibodies in Graves orbitopathy","volume":"27","author":"Jang","year":"2013","journal-title":"Eye (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Thyroid function and Graves ophthalmopathy","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/iop.0000000000001437","article-title":"Vitamin D deficiency and thyroid eye disease","volume":"36","author":"Heisel","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1478805","article-title":"Iodine contrast should be avoided in patients with thyroid eye disease","volume":"4","author":"Spadaro","year":"2024","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-24-0133","article-title":"The relationship between cholesterol levels and thyroid eye disease","volume":"14","author":"Cardo","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves' orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148","article-title":"Intravenous versus oral steroids in Graves orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1296092","article-title":"Orbital corticosteroid injections","volume":"3","author":"Eid","year":"2024","journal-title":"Front Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000000369","article-title":"Stereotactic navigation in orbital decompression","volume":"31","author":"Wu","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B17","first-page":"62","volume-title":"Basic and Clinical Science Course, Section 7: Oculofacial Plastic and Orbital Surgery","author":"Korn","year":""},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000593","article-title":"Balanced decompression for dysthyroid optic neuropathy","volume":"32","author":"Wu","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000000699","article-title":"Risk factors and outcomes in orbital decompression","volume":"33","author":"Wu","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2022.2100344","article-title":"Preventing relapse in Graves orbitopathy","volume":"17","author":"Campi","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.304","article-title":"Reactivation after orbital decompression","volume":"31","author":"Woo","year":"2017","journal-title":"Eye (Lond)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.10.036","article-title":"Reactivation after rehabilitative orbital decompression","volume":"114","author":"Baldeschi","year":"2007","journal-title":"Ophthalmology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06187-x","article-title":"Surgical effect in active vs inactive dysthyroid optic neuropathy","volume":"262","author":"Lv","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1210\/en.2018-00272","article-title":"Fibrotic remodeling in thyroid-associated orbitopathy","volume":"160","author":"Hikage","year":"2019","journal-title":"Endocrinology"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2026.1935053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:42:59Z","timestamp":1790656979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2026.1935053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":24,"alternative-id":["10.3389\/fopht.2026.1935053"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2026.1935053","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1935053"}}